Home Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited

Profile managed by Bizz Id

Japan 1781

Description

Takeda Pharmaceutical Company Limited runs a dedicated Plasma-Derived Therapies business unit, which it describes as more than twenty plasma medicines in more than eighty countries, with a network of eight plasma manufacturing facilities. This entry covers only that plasma and coagulation portfolio: intravenous and subcutaneous immunoglobulins, human albumin, alpha-1 proteinase inhibitor, protein C concentrate and anti-inhibitor coagulant complex, plus six recombinant coagulation products marked as such. Its pages name plasma sites in Covington (Georgia), Round Lake (Illinois) and Los Angeles (California) in the United States, Lessines in Belgium, Rieti and Pisa in Italy and Vienna in Austria, and state that plasma is collected through BioLife centres across the United States and Europe. Takeda publishes that the Round Lake site produces FLEXBUMIN and that the US FDA approved the Covington plant for the production of GAMMAGARD LIQUID. It is the company that took in, through Shire, the business that was Baxalta.

Products

17 products

ADAMTS13, recombinant-krhn

RECOMBINANT product, not plasma-derived. Brand ADZYNMA. Recombinant ADAMTS13. Published presentation: lyophilized powder in single-dose vials, 500 and 1500 IU nominal.

Tech pack available

Finished product (FDF)

Verified on 2026-10-17

ADAMTS13: see suppliers →

Albumin (Human) USP 25% solution

Brand FLEXBUMIN 25%. Plasma-derived albumin. Published presentation: 25%, 50 mL.

Tech pack available

Finished product (FDF)

Verified on 2026-10-17

Albumin: see suppliers →

Albumin (Human) USP 5% solution

Brand FLEXBUMIN 5%. Plasma-derived albumin in 5% solution.

Tech pack available

Finished product (FDF)

Verified on 2026-10-17

Albumin: see suppliers →

Alpha1-Proteinase Inhibitor (Human)

Brand ARALAST NP. Plasma-derived alpha1-proteinase inhibitor in a vial, supplied with Sterile Water for Injection as diluent. Published presentations: 0.5 g/25 mL and 1 g/50 mL.

Tech pack available

Finished product (FDF)

Verified on 2026-10-17

Alpha1-Proteinase Inhibitor: see suppliers →

Alpha1-Proteinase Inhibitor (Human), liquid

Brand GLASSIA. Plasma-derived alpha1-proteinase inhibitor, ready-to-use liquid. Published presentations: 1 g/50 mL, 4 g/200 mL and 5 g/250 mL.

Tech pack available

Finished product (FDF)

Verified on 2026-10-17

Alpha1-Proteinase Inhibitor: see suppliers →

Anti-Inhibitor Coagulant Complex

Brand FEIBA. Made from human plasma, indicated in hemophilia A and B patients with inhibitors. Published presentation: kit with BAXJECT II Hi-Flow and 50 mL diluent, 1750-3250 units.

Tech pack available

Finished product (FDF)

Verified on 2026-10-17

Anti-Inhibitor Coagulant Complex: see suppliers →

Antihemophilic Factor (Recombinant)

RECOMBINANT product, not plasma-derived. Brands ADVATE and RECOMBINATE. Recombinant factor VIII for hemophilia A. Published presentations: ADVATE kit with BAXJECT III and 2 mL diluent; RECOMBINATE kit with BAXJECT II and 5 mL diluent.

Tech pack available

Finished product (FDF)

Verified on 2026-10-17

Factor VIII: see suppliers →

Antihemophilic Factor (Recombinant), PEGylated

RECOMBINANT product, not plasma-derived. Brand ADYNOVATE. PEGylated recombinant factor VIII for hemophilia A. Published presentation: kit with BAXJECT III and 2 mL diluent, 1200-1875 IU.

Tech pack available

Finished product (FDF)

Verified on 2026-10-17

Factor VIII: see suppliers →

Antihemophilic Factor (Recombinant), Porcine Sequence

RECOMBINANT product, not plasma-derived. Brand OBIZUR. Porcine-sequence recombinant factor VIII. Published presentation: lyophilized powder for intravenous injection, 500 units, one-vial package.

Tech pack available

Finished product (FDF)

Verified on 2026-10-17

Factor VIII: see suppliers →

Coagulation Factor IX (Recombinant)

RECOMBINANT product, not plasma-derived. Brand RIXUBIS. Recombinant factor IX for hemophilia B. Published presentation: kit with BAXJECT II and 5 mL diluent, 1400-2600 IU per vial.

Tech pack available

Finished product (FDF)

Verified on 2026-10-17

Factor IX: see suppliers →

Immune Globulin Infusion (Human) 10% solution

Brand GAMMAGARD LIQUID. Plasma-derived immune globulin; for primary immunodeficiency by intravenous or subcutaneous route and for CIDP and MMN by intravenous route only. Published presentation: 5 g/50 mL 10%.

Tech pack available

Finished product (FDF)

Covington GA

US FDA

Verified on 2026-10-17

Immunoglobulin: see suppliers →

Immune Globulin Infusion (Human) 10% solution with IgA less than or equal to 2 micrograms/mL

Brand GAMMAGARD LIQUID ERC. Plasma-derived immune globulin with IgA less than or equal to 2 µg/mL via the ERC (Enhanced Removal Capability) process, for primary immunodeficiency. Published presentation: 10 g 10%.

Tech pack available

Finished product (FDF)

Verified on 2026-10-17

Immunoglobulin: see suppliers →

Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase

Brand HYQVIA. Plasma-derived immune globulin 10% for subcutaneous use, with recombinant human hyaluronidase. Published presentation: 2.5 g.

Tech pack available

Finished product (FDF)

Verified on 2026-10-17

Immunoglobulin: see suppliers →

Immune Globulin Intravenous (Human) 5% solution

Brand GAMMAGARD S/D. Plasma-derived intravenous immune globulin with IgA less than 1 µg/mL. Published presentation: 10 g 5%.

Tech pack available

Finished product (FDF)

Verified on 2026-10-17

Immunoglobulin: see suppliers →

Immune Globulin Subcutaneous (Human) 20% solution

Brand CUVITRU. Plasma-derived subcutaneous immune globulin for primary immunodeficiency. Published presentations: 1 g, 4 g/20 mL, 8 g and 10 g.

Tech pack available

Finished product (FDF)

Verified on 2026-10-17

Immunoglobulin: see suppliers →

Protein C Concentrate (Human)

Brand CEPROTIN. Plasma-derived protein C concentrate, lyophilized powder for solution for injection. Published presentation: 500 IU single-dose vial.

Tech pack available

Finished product (FDF)

Verified on 2026-10-17

Protein C: see suppliers →

von Willebrand factor (Recombinant)

RECOMBINANT product, not plasma-derived. Brand VONVENDI. Recombinant von Willebrand factor. Published presentation: kit with 5 mL diluent, 450-850 IU.

Tech pack available

Finished product (FDF)

Verified on 2026-10-17

Von Willebrand factor: see suppliers →

Certifications

US FDA

Contact company

Other locations

Covington GA
Covington GA (Estados Unidos)

Round Lake IL
Round Lake IL (Estados Unidos)

Los Angeles CA
Los Angeles CA (Estados Unidos)

Lessines
Lessines (Bélgica)

Viena
Viena (Austria)

Rieti
Rieti (Italia)

Pisa
Pisa (Italia)